Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-017
- Development stage
- Preclinical
- Lead developer
- Chengdu Lingtai Krypton Biotechnology
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
LT-017 is a preclinical long non-coding RNA (lncRNA)-based therapeutic being developed by lncTAC (Chengdu Lingtai Krypton Biotechnology) for the treatment of respiratory diseases. The drug is designed using lncTAC's proprietary lncRNA-based platform and is delivered via a respiratory delivery platform. It is currently in preclinical development.
Beyond the preview
Go deeper on LT-017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LT-017.